Genetic Immunity, a leader in plasmid DNA-based immunotherapies, and VectorBuilder, a global specialist in gene delivery solutions, announced a strategic partnership to advance Genetic Immunity's ...

The new Dogma meets Thomas Kuhn’s definition of a paradigm shift. The DNA/RNA Dogma is sufficiently unprecedented to attract ...

Viral Vector Development MarketThe Viral Vector Development Market is set for impressive growth, with its valuation expected to rise from USD 730.7 million in 2023 to USD 4.1 billion by 2033, ...

Next-generation sequencing allows for critical insights into gene therapy products, which can help streamline and accelerate ...

Delve into the expanding and diverse field of cancer vaccines with various approaches exploiting the immune system to fight ...

at 07:05 Genetic Immunity (GI) Leverages VectorBuilder Partnership to Power Phase 3 HIV Vaccine Trials Genetic Immunity, a leader in plasmid DNA-based immunotherapies, and VectorBuilder, a global ...

Discover various promising treatments in development to address the unmet needs of people with Charcot–Marie–Tooth disease.

Department of Microbiolog, Immunology, and Biochemistry. University of Tennessee Health Science Center, Memphis, USA ...

Thanks to technological advancements in nucleic acid sequencing and the shift toward molecular research and personalized medicine, omics approaches have become increasingly important in studying the ...

Charles River Laboratories International, Inc. CRL continues to enhance its portfolio through targeted partnerships and acquisitions, poised to drive growth in the upcoming quarters. The company’s RMS ...

A new study finds that two subtypes of pathogenic Escherichia coli (E. coli) produce five to 16 times more protective capsular “slime” when Enterococcus faecalis (EF) is present. The finding could ...

Oct. 28, 2024 — Using state-of-the-art technology, researchers have identified several specific steps needed for CRISPR to become active and perform its gene editing function. These preclinical ...